Aktis Oncology, Inc. (AKTS) CFO discloses initial stock option holdings

Rhea-AI Filing Summary

Aktis Oncology, Inc. Chief Financial Officer Kyle D. Kuvalanka filed an initial Form 3 reporting his beneficial ownership of stock options in the company. He directly holds a stock option to buy 370,423 shares of common stock at an exercise price of $11.46 per share, exercisable until 12/11/2035, and another option to buy 131,426 shares at $18 per share, exercisable until 01/07/2036.

For the first option grant, 25% of the shares will vest on November 3, 2026, with the remainder vesting in equal monthly installments over the following three years, subject to his continued service. For the second grant, 25% of the shares will vest on January 8, 2027, with the balance vesting monthly thereafter on the same continued-service condition. The filing does not show any stock sales or purchases, only these option holdings.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kuvalanka Kyle D.

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	12/11/2035	Common Stock	370,423	$11.46	D
Stock Option (Right to Buy)	(2)	01/07/2036	Common Stock	131,426	$18	D

Explanation of Responses:

1. 25% of the original number of shares subject to the option shall vest on November 3, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

2. 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kyle D. Kuvalanka	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Aktis Oncology (AKTS) Form 3 filing disclose?

The Form 3 discloses that CFO Kyle D. Kuvalanka beneficially owns two stock option grants giving him the right to buy Aktis Oncology common stock at fixed exercise prices.

How many Aktis Oncology stock options does the CFO hold?

He holds a stock option for 370,423 shares of common stock at an exercise price of $11.46 per share and another option for 131,426 shares at $18 per share.

When do the CFO’s Aktis Oncology stock options vest?

For the first option, 25% vests on November 3, 2026, with the remaining shares vesting in equal monthly installments thereafter. For the second, 25% vests on January 8, 2027, with the remainder vesting monthly thereafter, in both cases subject to his continuous service.

Did the Aktis Oncology CFO buy or sell any shares in this Form 3?

No. The Form 3 reports holdings of stock options only. It does not show any purchases or sales of Aktis Oncology common stock.

Is the CFO’s ownership direct or through another entity in this filing?

The Form 3 lists both stock option positions as held with direct (D) ownership and does not reference any indirect ownership entities.

What are the expiration dates of the Aktis Oncology stock options reported?

The first stock option expires on 12/11/2035, and the second stock option expires on 01/07/2036.